Company intelligence / Profile preview

LAVVAN

New York, New York, United States

Ownership: Private
Employees: ~6
Development stage: Other

Overview

LAVVAN develops and commercializes fermentation‑derived, high‑purity natural cannabinoid ingredients using a proprietary cellular agriculture platform, targeting use in health, wellness, pharmaceutical and consumer products rather than running its own clinical drug programs.[1][2][3]

Modalities: Small molecule
Industry: Non-Drug Biotech

Partnerships

Amyris (research, collaboration, license, development and commercialization of fermentation‑derived cannabinoids, deal announced March 2019 and valued up to $300 million).[3][5][6]

Beyond the preview

Go deeper on LAVVAN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAVVAN.

Explore the full profile